0115 837 0503 info@aureliabio.com

3-D Cell Biology

We have developed a 3-D micro-tissue system from electrospun material that can be used in conjunction with well plates for higher throughput screening. Additionally, we use Ultra Low Attachment (ULA) plates to generate and culture spheroids.

Phenotypic Screening

We specialise in physiologically relevant assays using cell-based formats in state of the art technologies. We have used a number of human primary cells in a number of assay formats.

WES: Western Assay System

The WesTM system from ProteinSimple is a fully automated device which runs the Simple Western size assay; a highly reproducible and sensitive alternative to standard Western blotting assays.

High Content Screening

High Content Screening (HCS) uses microscopic imaging to observe, measure and analyse multiple parameters within cells in a biological assay.

Label-Free Screening

Our scientists have in-depth experience of label-free technology applied to cell-based assays gained over the past 6 years using Corning Epic, PerkinElmer EnSpire and SRU Bioscience Bind instruments.


PROTAC (PROtein TArgeted Chimeric) is the ability to specifically degrade a protein using the endogenous machinery of the cell. We have developed assays for PROTAC using WES (ProteinSimple) and NanoLuc (Promega). 

Cell-Based Screening

Cell based assays are of key importance at a number of stages in the drug discovery process. Being able to examine the interaction between your target and compounds in a cellular context is of great advantage.

High Throughput Screening

With over 20 years of screening experience we are adept at designing screening assays and screening 100,000 to 1 million compounds in 384 well and 1536 well plates.

FLIPR Screening

We use FLIPR in a range of assay formats, readouts and target types.

Kinase Compound Profiling

Using Promega’s NanoBRET™ technology, we have employed intracellular kinase assays designed to study the interaction of compounds on kinase targets in intact living cells.

Cell Culture Services

Typical screens have required upwards of 1010 cells. We have developed methodologies to grow, sub-culture, harvest, cryopreserve and revive these quantities of cells from single batches, thus reducing screening variability, allowing cells to be used in an identical manner to other assay reagents, reviving and using what is required on a daily basis.

Flow Cytometry

Flow cytometry can simultaneously analyse multiple parameters such as relative size, internal complexity, relative fluorescence intensity, etc on the same cell within seconds. 

Protein-Protein Interactions

We have successfully used NanoBRET™ System (Promega) to detect protein- protein interactions in living cells.   

Quantitative PCR

Using our Applied Biosystems™ QuantStudio™ 6 Flex Real-Time PCR system, we are able to investigate quantitative differences in mRNA expression in relation to pathways and targets identified as being of interest to clients. 

Biochemical Screening

We have carried out biochemical screening for a range of targets including but not limited to proteases, kinases, phosphodiesterase enzymes and protein:protein interactions.

Instrument and Reagent Validation

Acting as an intermediary between instrument manufacturers and reagent manufacturers and prospective clients, we can provide an expert lab-based environment for the validation of new technologies.

Hypoxia and Cancer

We have developed a physiologically relevant human cell-based assay to screen small molecules for their ability to inhibit adaptive responses to hypoxia.

Customised bioassay development, pharmacological profiling and compound screening

Job vacancy: Senior Assay Development Scientist – Drug Discovery

Location: Nottingham NG1 1GF Salary: Highly competitive Type: Permanent, full time Are you an Assay Development Scientist with experience within a contract research or similar drug discovery environment, looking for a new opportunity to develop your career within a...

Webinar: Advancing Targeted Protein Degradation Research with Automated Western Blotting

Our CEO, Dr. Gary Allenby, talked on Advancing Targeted Protein Degradation Research with Automated Western Blotting WESS and JESS) at a webinar organised by Bio-Techne earlier this month. If you missed it, but would like to access it, follow the link.  

Expert CROs join forces to support the discovery and development of new therapeutics during the pandemic

Nottingham-based contract research organisations (CROs) have strengthened their existing links to work together and support the discovery and development of new therapeutics during the pandemic. Many businesses have been impacted by the restrictions on the movement of...

Webinar: Cell-based screening

Our CEO, Dr. Gary Allenby, talked on 'Cell-based screening: Old dogs with new tricks' at a webinar organised by Medicines Discovery Catapult on 29th April. If you missed it, but would like to access the slides, follow the link.  

Blog: PROTAC Assays- Successfully measuring Protein Degradation

PROTAC (PROteolysis TArgeting Chimera) is one of the hottest topics in drug discovery today as it is a highly promising new approach to targeted therapy. It offers several advantages over traditional occupancy-based drugs, with a potential to target the ‘undruggable’...

International Women’s Day 2020

As we celebrate International Women's Day 2020, we would like to dedicate a short clip to all the wonderful ladies of Aurelia Bioscience family..thanking them for all their dedication, hard work and support.  

Are you looking for a CRO to help you discover your next breakthrough drug?